Table 1.

Baseline Characteristics of the Total Study Cohort and the Microneurography Cohort

	Total Cohort (n=26)		Microneurography Cohort (n=18)
	Atorvastatin Group (n= 14)	Placebo Group (n=12)	Atorvastatin Group (n = 9)	Placebo Group (n = 9)
Age, years	47 ± 14	49 ± 17	47 ± 15	46 ± 19
Male, %	42^*	86	44^*	89
Systolic Blood Pressure, mmHg	100 ± 13	101 ± 13	96 ± 11	98 ± 9
Diastolic Blood Pressure, mmHg	65 ± 9	61 ± 8	66 ± 11	60 ± 10
Heart Rate, bpm	74 ± 11	71 ± 8	73 ± 8	71 ± 8
Body Mass Index, kg/m²	31 ± 7	31 ± 6	29 ± 4	33 ± 6
NYHA I/II/III, %	7/71/21	0/92/8	11/67/22	0/89/11
LVEF, %	24 ± 6	28 ± 7	24 ± 6	29 ± 6
Left ventricular end diastolic dimension, mm	65 ± 12	66 ± 11	65 ± 13	66 ± 8
Peak oxygen uptake, ml/kg/min	15.6 ± 4.1	16.6 ± 5.2	16.0 ± 3.6	15.9 ± 5.8
Laboratory Values
Total cholesterol, mg/dL	185 ± 34	187 ± 39	182 ± 37	188 ± 44
LDL cholesterol, mg/dL	106 ± 24	110 ± 29	101 ± 23	108 ± 28
HDL cholesterol, mg/dL	49 ± 13	41 ± 10	49 ± 14	42 ± 12
Triglycerides, mg/dL^†	151 (66 – 235)	177 (87 – 226)	187 (66–245)	193 (89–267)
High sensitivity C-reactive protein, mg/dL^†	1.6 (0.6 – 4.4)	1.9 (1.0 – 3.0)	1.7 (0.8 – 3.7)	2.1 (0.8 – 4.2)
B-type natriuretic peptide, pg/mL^†	176 (36 – 472)	55 (29 – 154)	185 (53 – 482)	66 (32–115)
Creatinine, mg/dL	0.9 ± 0.2^*	1.2 ± 0.4	1.0 ± 0.2	1.1 ± 0.3
Alanine transferase (ALT), U/L	22 ± 10	26 ± 12	24 ± 10	29 ± 13
Aspartate transferase (AST), U/L	22 ± 7	24 ± 7	24 ± 7	24 ± 9
Medications
Beta-blocker, %	100	100	100	100
Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker, %	100	100	100	100
Aldosterone Antagonist, %	83	71	88	88
Loop diuretic, %	66	79	67	88
Digoxin, %	17	43	11	44

p<0.05 atorvastatin vs. placebo groups

^†

Median and interquartile range reported